Hysone

Hysone Drug Interactions

hydrocortisone

Manufacturer:

GPO

Distributor:

GPO
Full Prescribing Info
Drug Interactions
Barbiturates: Decreased pharmacologic effects of the corticosteroid may be observed.
Cholestyramine: The hydrocortisone AUC may be decreased.
Oral contraceptives: Corticosteroid half-life and concentration may be increased and clearance decreased.
Estrogens: Corticosteroid clearance may be decreased.
Hydantoins: Corticosteroid clearance may be increased, resulting in reduced therapeutic effects.
Ketoconazole: Corticosteroid clearance may be decreased and the AUC increased.
Rifampin: Corticosteroid clearance may be increased, resulting in reduced therapeutic effects.
Anticholinesterases: Anticholinesterase effects may be antagonized in myasthenia gravis.
Oral anticoagulants: Anticoagulant dose requirement may be reduced. Conversely, corticosteroids may oppose the anticoagulant action.
Cyclosporine: Although this combination is therapeutically beneficial for organ transplants, toxicity may be enhanced.
Digitalis glycosides: Coadministration may enhance the possibility of digitalis toxicity associated with hypokalemia.
Isoniazid: Isoniazid serum concentrations may be decreased.
Nondepolarizing muscle relaxants: Corticosteroids may potentiate, counteract, or have no effect on the neuromuscular blocking action.
Potassium-depleting agents (eg, diuretics): Observe patients for hypokalemia.
Salicylates: Corticosteroids will reduce serum salicylate levels and may decrease their effectiveness.
Somatrem: Growth-promoting effect of somatrem may be inhibited.
Theophyllines: Alterations in the pharmacologic activity of either agent may occur.
Macrolide antibiotics eg, erythromycin: Erythromycin may inhibit the metabolism of corticosteroids.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in